584 related articles for article (PubMed ID: 20456733)
81. [Use of statins in children].
Tapia Ceballos L; Picazo Angelín B; Ruiz García C
An Pediatr (Barc); 2008 Apr; 68(4):385-92. PubMed ID: 18394386
[TBL] [Abstract][Full Text] [Related]
82. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
Gerards MC; Terlou RJ; Yu H; Koks CH; Gerdes VE
Atherosclerosis; 2015 Jun; 240(2):415-23. PubMed ID: 25897793
[TBL] [Abstract][Full Text] [Related]
83. Comparative analysis of the efficacy of low- and moderate-intensity statins in Korea.
Kim HS; Lee H; Park B; Park S; Kim H; Lee SH; Cho JH; Yoon KH; Cha BY; Kim JH; Choi IY
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):864-871. PubMed ID: 27487366
[TBL] [Abstract][Full Text] [Related]
84. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial.
Upala S; Wirunsawanya K; Jaruvongvanich V; Sanguankeo A
Int J Cardiol; 2017 Jan; 227():338-341. PubMed ID: 27839806
[TBL] [Abstract][Full Text] [Related]
85. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.
Barter PJ; Brandrup-Wognsen G; Palmer MK; Nicholls SJ
J Lipid Res; 2010 Jun; 51(6):1546-53. PubMed ID: 19965573
[TBL] [Abstract][Full Text] [Related]
86. Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis.
Sahebkar A
Metabolism; 2013 Dec; 62(12):1876-85. PubMed ID: 24095632
[TBL] [Abstract][Full Text] [Related]
87. The influence of statin characteristics on their safety and tolerability.
De Angelis G
Int J Clin Pract; 2004 Oct; 58(10):945-55. PubMed ID: 15587774
[TBL] [Abstract][Full Text] [Related]
88. [Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin].
Bart BY; Luchinkina EE; Gordeev IG; Arutyunov GP; Taratukhin On Behalf Of The Workgroup Of Paritet Trial EO
Kardiologiia; 2016 Jun; 56(6):46-49. PubMed ID: 28290847
[TBL] [Abstract][Full Text] [Related]
89. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
[No Abstract] [Full Text] [Related]
90. Variations in time to benefit among clinical trials of cholesterol-lowering drugs.
Barter PJ; Waters DD
J Clin Lipidol; 2018; 12(4):857-862. PubMed ID: 29779997
[TBL] [Abstract][Full Text] [Related]
91. Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry.
Bae HJ; Cho YK; Park HS; Yoon HJ; Kim H; Han S; Hur SH; Kim YN; Kim KB; Ryu JK; Nah DY; Nam CW
Korean J Intern Med; 2020 Mar; 35(2):342-350. PubMed ID: 31422649
[TBL] [Abstract][Full Text] [Related]
92. Statin use and the risk of developing diabetes: a network meta-analysis.
Thakker D; Nair S; Pagada A; Jamdade V; Malik A
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1131-1149. PubMed ID: 27277934
[TBL] [Abstract][Full Text] [Related]
93. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins.
Naci H; Dias S; Ades AE
BMJ; 2014 Oct; 349():g5741. PubMed ID: 25281681
[TBL] [Abstract][Full Text] [Related]
94. Systematic review on the risk and benefit of different cholesterol-lowering interventions.
Bucher HC; Griffith LE; Guyatt GH
Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):187-95. PubMed ID: 9974397
[TBL] [Abstract][Full Text] [Related]
95. Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.
Al-Badriyeh D; Fahey M; Alabbadi I; Al-Khal A; Zaidan M
Clin Ther; 2015 Dec; 37(12):2798-810. PubMed ID: 26299479
[TBL] [Abstract][Full Text] [Related]
96. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization.
Spearman ME; Summers K; Moore V; Jacqmin R; Smith G; Groshen S
Clin Ther; 1997; 19(3):582-602; discussion 538-9. PubMed ID: 9220221
[TBL] [Abstract][Full Text] [Related]
97. Clinically relevant differences between the statins: implications for therapeutic selection.
Chong PH; Seeger JD; Franklin C
Am J Med; 2001 Oct; 111(5):390-400. PubMed ID: 11583643
[TBL] [Abstract][Full Text] [Related]
98. Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials.
Huang Y; Li W; Dong L; Li R; Wu Y
J Atheroscler Thromb; 2013; 20(1):108-21. PubMed ID: 23095240
[TBL] [Abstract][Full Text] [Related]
99. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis.
Genser B; Grammer TB; Stojakovic T; Siekmeier R; März W
Int J Clin Pharmacol Ther; 2008 Oct; 46(10):497-510. PubMed ID: 18826864
[TBL] [Abstract][Full Text] [Related]
100. A prospective study of hepatic safety of statins used in very elderly patients.
Guo M; Zhao J; Zhai Y; Zang P; Lv Q; Shang D
BMC Geriatr; 2019 Dec; 19(1):352. PubMed ID: 31842780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
